NCT00775632 - Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Graft Versus Host DiseaseBone Marrow Transplantation

Interventions

DRUG

Alemtuzumab

A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.

DRUG

mycophenolate or cyclosporine and methotrexate

One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto